Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- 100, Novartis Investigational Site
-
-
Queensland
-
Auchenflower, Queensland, Australien, 4066
- 108, Novartis Investigational Site
-
Sherwood, Queensland, Australien, 4075
- 107, Novartis Investigational Site
-
-
South Australia
-
North Adelaide, South Australia, Australien, 5006
- 104, Novartis Investigational Site
-
-
Victoria
-
Carlton, Victoria, Australien, 3010
- 103, Novartis Investigational Site
-
-
Western Australia
-
Subiaco, Western Australia, Australien, 6008
- 105, Novartis Investigational Site
-
-
-
-
Alabang
-
Muntinlupa City, Alabang, Filippinerne, 1781
- 250, Novartis Investigational Site
-
Muntinlupa City, Alabang, Filippinerne, 1781
- 251, Novartis Investigational Site
-
Muntinlupa City, Alabang, Filippinerne, 1781
- 254, Novartis Investigational Site
-
-
Ermita
-
Manila, Ermita, Filippinerne, 1001
- 253, Novartis Investigational Site
-
-
Sampaloc
-
Manila, Sampaloc, Filippinerne, 1001
- 252, Novartis Investigation Site
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36608
- 320, Novartis Investigational Site
-
-
Florida
-
Ponte Vedra, Florida, Forenede Stater, 32081
- 312, Novartis Investigational Site
-
-
Kansas
-
Augusta, Kansas, Forenede Stater, 67010
- 313, Novartis Investigational Site
-
Newton, Kansas, Forenede Stater, 67114
- 305, Novartis Investigational Site
-
Wichita, Kansas, Forenede Stater, 67205
- 302, Novartis Investigational Site
-
Wichita, Kansas, Forenede Stater, 67207
- 301, Novartis Investigational Site
-
-
Nebraska
-
Fremont, Nebraska, Forenede Stater, 68025
- 311, Novartis Investigational Site
-
-
North Carolina
-
Winston-salem, North Carolina, Forenede Stater, 27103
- 308, Novartis Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44121
- 317, Novartis Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74127
- 309, Novartis Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, Forenede Stater, 02886
- 314, Novartis Investigational Site
-
-
South Carolina
-
Mount Pleasant, South Carolina, Forenede Stater, 29464
- 319, Novartis Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, Forenede Stater, 37620
- 310, Novartis Investigational Site
-
Nashville, Tennessee, Forenede Stater, 37203
- 318, Novartis Investigational Site
-
-
Utah
-
Salt Lake, Utah, Forenede Stater, 84124
- 315, Novartis Investigational Site
-
Salt Lake City, Utah, Forenede Stater, 84109
- 304, Novartis Investigational Site
-
Salt Lake City, Utah, Forenede Stater, 84121
- 306, Novartis Investigational Site
-
South Jordan, Utah, Forenede Stater, 84095
- 303, Novartis Investigational Site
-
-
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0622
- 151, Novartis Investigational Site
-
-
Christchurch
-
Beckenham, Christchurch, New Zealand, 8024
- 150, Novartis Investigational Site
-
-
-
-
Muang
-
Khon Kaen, Muang, Thailand, 40002
- 201, Novartis Investigational Site
-
-
Rajathevi
-
Bangkok, Rajathevi, Thailand, 10400
- 200, Novartis Investigational Site
-
-
Siriraj
-
Bangkoknoi, Siriraj, Thailand, 10700
- 202, Novartis Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy subjects 4-17 years of age
Exclusion Criteria:
- Subjects who are not healthy,
- Subjects who are pregnant or breast feeding,
- Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: TIVc
Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
|
|
|
Aktiv komparator: TIVf
Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.
Tidsramme: Day 1 to Day 7 after any vaccination
|
Safety was assessed as the number of subjects who reported solicited local and systemic adverse events and other indicators of reactogenicity following two doses of either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day 7 after any vaccination
|
|
Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.
Tidsramme: Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.
|
Safety was assessed as the number of subjects who reported unsolicited adverse events following vaccination with either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.
|
|
Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.
Tidsramme: Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects
|
Safety was assessed as the number of subjects who reported serious adverse events (SAEs), medically attended AEs and new onset of chronic diseases (NOCD) in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- V58_31
- U1111-1139-9440 (Anden identifikator: Universal Trial Number (UTN))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .